Jamjoom Pharma gets SFDA approval to register eye drop facility in Jeddah

Logo of Jamjoom Pharmaceuticals Factory Co.

Jamjoom Pharmaceuticals Factory Co. received the Saudi Food and Drug Authority’s (SFDA) approval to register the new sterile facility (ophthalmic products) in Jeddah.

In a statement to Tadawul, the company said the state-of-the-art facility is built on an area of 7,500 sqm in phase 5 of Jeddah industrial city. The construction costs are approximately SAR 200 million.

The facility specializes in producing sterile products (ophthalmic products), and its annual production capacity will reach 25 million units at full operations, the statement noted.

Commercial production will commence after relevant products approvals are obtained from the SFDA.